Your session is about to expire
← Back to Search
Pembrolizumab for Breast Cancer
Study Summary
This trial is testing if adding immunotherapy to chemotherapy can help control hormone receptor positive breast cancer that has spread.
- Breast Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a history of a lung disease called interstitial lung disease.If you are taking medication called bisphosphonates or denosumab, you can still participate in the study and continue taking those medications.You have had allergic reactions to medicines that are similar to eribulin mesylate or pembrolizumab.You have had a lung condition called pneumonitis in the past that needed treatment with steroids.You are not currently taking any experimental drugs.
- Group 1: Eribulin Mesylate Combine with Pembrolizumab
- Group 2: Eribulin Mesylate
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What adverse effects have been observed in patients who take Pembrolizumab?
"Given the Phase 2 status of Pembrolizumab, our team at Power rated its safety as a 2. This score is based on existing data that confirms it has some level of safety but no evidence yet to support efficacy."
What is the aggregate amount of individuals partaking in this experiment?
"Currently, this trial is not enrolling new patients. It was first posted on March 22nd 2017 and last modified April 18th 2022. For individuals hoping to explore other options, there are 2600 different studies involving breast cancer currently recruiting participants as well as 995 clinical trials examining the efficacy of Pembrolizumab."
What goals is this research attempting to accomplish?
"This trial's primary aim is to measure Progression Free Survival. Secondary goals include assessing the Objective Response Rate and determining the safety and efficacy of pembrolizumab after progression on eribulin mesylate monotherapy. Disease assessments are conducted every 3 weeks for 18 cycles, while follow-up data collection will last up to 10.5 months with a range between 0.43 - 19 months. ORR is determined by complete disappearance or at least 30% decrease in target lesions per RECIST 1.1 criteria respectively; Overall response must meet incomplete/stable disease requirements for non-target lesions and no new lesion development as"
Is participation in this scientific investigation still available?
"According to the records on clinicaltrials.gov, this medical experiment is no longer recruiting participants; the first posting was made on March 22nd 2017 and it has since been updated for the last time on April 18th 2022. Nevertheless, there are 3595 other studies that may be seeking volunteers right now."
What other research has been carried out regarding the efficacy of Pembrolizumab?
"At the moment, 995 studies concerning Pembrolizumab are being conducted; 132 of those experiments are in Phase 3. Although Houston, Texas is where most trials take place, there are 36946 seperate locations running investigations into this particular treatment."
What maladies are often remedied with Pembrolizumab?
"Pembrolizumab can be utilized to ameliorate malignant neoplasms, unresectable melanoma, and microsatellite instability high cases."
Share this study with friends
Copy Link
Messenger